台股 » 個股 » 逸達 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

逸達

(6576)
  • 股價
    79.9
  • 漲跌
    ▼1.7
  • 漲幅
    -2.08%
  • 成交量
    220
  • 產業
    上櫃 生技醫療類股
  • 117人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
逸達 (6576)籌碼相關-凱基-大里 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

凱基-大里 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2026/07/16181.4000.0081.6011850.54%
2026/07/15181.5000.0081.7011930.52%
2026/07/1300.00381.6382.00-3194-1.54%
2026/07/0900.00182.8083.10-1190-0.52%
2026/07/08184.10484.3584.10-3188-1.59%
2026/07/07183.5000.0084.9011830.54%
2026/07/0600.00184.2083.50-1180-0.55%
2026/07/0300.00283.0083.20-2177-1.13%
2026/07/0100.00180.3080.30-1170-0.59%
2026/06/2900.001181.4481.30-11169-6.49%
2026/06/2400.00179.1079.10-1162-0.61%
2026/06/23179.0000.0079.6011620.61%
2026/06/17478.8000.0078.8041562.56%
2026/06/1500.00178.3078.30-1158-0.63%
2026/06/09378.7700.0078.4031561.92%
2026/06/02375.90176.0076.0021581.26%
2026/06/01276.0000.0076.8021571.27%
2026/05/2900.00477.0077.00-4159-2.50%
2026/05/28377.8000.0077.6031601.87%
2026/05/27178.3000.0078.1011620.61%
2026/05/26278.4000.0078.5021641.22%
2026/05/25179.00278.4078.40-1165-0.60%
2026/05/22180.50380.5080.50-2164-1.22%
2026/05/2100.00982.0881.80-9163-5.50%
2026/04/20275.35175.9075.9011740.57%
2026/04/17276.05276.6076.6001680.00%
2026/04/16176.50277.0077.00-1168-0.59%
2026/04/151076.8300.0077.00101685.93%
2026/04/13276.65277.0077.0001670.00%
2026/04/10176.5000.0077.2011690.59%
2026/04/09177.10177.2077.2001680.00%
2026/04/08577.78377.5077.5021681.18%
2026/03/31175.50176.6076.6001770.00%
2026/03/27277.0500.0077.7021791.11%
2026/03/2600.00177.7077.70-1183-0.54%
2026/03/24276.9500.0077.3021831.09%
2026/03/23176.3000.0076.8011840.54%
2026/03/20477.2500.0077.0041822.19%
2026/03/19377.53178.0078.0021811.10%
2026/03/18178.40278.4078.40-1179-0.56%
2026/03/17178.90178.8078.8001770.00%
2026/03/1100.00280.9081.10-2176-1.14%
2026/03/10180.4000.0080.7011730.58%
2026/03/06181.2000.0081.6011730.58%
2026/03/05280.7500.0080.8021731.15%
2026/02/2500.00282.9082.90-2176-1.14%
2026/02/2400.00283.5083.50-2177-1.13%
2026/02/23182.80283.9083.90-1179-0.56%
2026/02/11184.7000.0084.6011900.53%
2026/02/06184.80486.2087.00-3230-1.30%
2026/02/02183.50183.4083.7002210.00%
2026/01/2200.00179.7079.70-1209-0.48%
2026/01/2000.00179.9079.90-1208-0.48%
2026/01/1900.00180.0080.00-1208-0.48%
2026/01/16181.2000.0080.9012050.49%
2026/01/14179.40280.0080.00-1203-0.49%
2026/01/13179.7000.0080.0012040.49%
2026/01/08179.5000.0079.8012100.47%
2025/12/29180.0000.0080.9012220.45%
2025/12/2600.00882.2482.00-8219-3.64%
2025/12/11178.4000.0079.4012230.45%
2025/12/10378.8000.0079.4032281.31%
2025/12/09179.4000.0079.4012340.43%
2025/11/26174.5000.0074.4012880.35%
2025/11/25273.00472.9072.90-2298-0.67%
2025/11/2400.00173.8073.80-1299-0.33%
2025/11/21174.20274.0074.00-1314-0.32%
2025/11/18174.3000.0076.3013090.32%
2025/11/17182.2000.0080.6013060.33%
2025/11/07177.3000.0077.0012600.38%
2025/11/06277.1000.0077.2022630.76%
2025/11/04877.31277.0077.0062632.27%
2025/10/31478.4000.0078.6042671.50%
2025/10/30178.10178.5078.5002770.00%
2025/10/29178.7000.0078.8012800.36%
2025/10/28277.50178.2078.2012810.35%
2025/10/23378.3000.0078.9032801.07%
2025/10/21179.00279.0079.00-1279-0.36%
2025/10/1300.00179.8081.20-1268-0.37%
2025/10/07180.50181.8081.8002640.00%
2025/09/24183.4000.0083.8012510.40%
2025/09/2200.00384.3084.30-3252-1.19%
2025/09/1700.00181.7081.70-1243-0.41%
2025/09/0800.00184.9084.30-1215-0.46%
2025/09/0500.00282.1084.20-2210-0.95%
2025/09/0400.00182.4082.70-1198-0.50%
2025/09/0300.001882.7383.40-18199-9.03%
2025/09/0200.00178.8080.00-1192-0.52%
2025/09/01177.70178.7077.7001890.00%
2025/08/292274.7500.0077.502218411.91%
2025/08/2800.00180.0080.00-1175-0.57%
2025/08/2200.00281.1081.40-2142-1.41%
2025/08/2100.001681.9081.90-16141-11.30%
2025/08/2000.00583.7082.00-5140-3.57%
2025/08/1900.00378.7378.80-3129-2.31%
2025/08/1800.001277.8377.90-12128-9.31%
2025/08/13175.3000.0074.8011250.80%
2025/08/1200.00175.4075.40-1125-0.80%
2025/08/0400.00576.5080.20-5120-4.16%
2025/07/2100.001074.2173.80-10110-9.09%
逸達SIF技術平台跨足中樞神經系統領域 兩項候選藥物明年進入人體臨床試驗Anue鉅亨-2026/05/22
逸達 相關文章
逸達 相關影音